Trial
NCT03256045
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI); SecuraBio
Condition
Recurrent Plasma Cell Myeloma
Intervention
Carfilzomib
Why stopped
Terminated due to loss of funding and former PI left the institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-09